BioSpace News Archive

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced it was awarded $4.7 million from the U.S. Army Medical Research & Development Command to fund its Phase 1/2 clinical trial of T-COVID, an investigational intranasal immune modulator for the treatment of outpatients with early COVID-19.

Kraig Biocraft Laboratories, Inc., a leading developer of spider silk based fibers, announces that it has completed the development phase of a new program targeting the largest challenge facing global silk production, viral pathogens.

Cancer Access Partnership is expected to result in a 59 percent savings on procured cancer medicines

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, announced that management will participate in the following upcoming virtual investor conferences

CytoSorbents Corporation announces that CytoSorbents will host a Key Opinion Leader call on the Use of CytoSorb to Remove Antithrombotic Medications in Patients at Risk of Bleeding, on Monday, July 13, 2020 at 11:00 AM EDT, featuring presentations by key experts:

XOMA Corporation (Nasdaq: XOMA) today announced the Company has been added to the Russell 2000 ® and Russell 3000 ® Indexes following the annual reconstitution, which took effect after the U.S. market closed on June 26, 2020. “We expect XOMA’s addition to these Russell indexes will enhance the Company’s visibility in the investment community and broaden our shareholder base,” stated Jim Neal, Chief Executive Officer of XOMA. The Russe

Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBD IND filing on track for mid-year and phase 1 clinical trial expected third-quarter 2020 WALTHAM, Mass., June 29, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced a presentation highlightin

Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli.

AVITA Medical Limited ACN 058 466 523 is pleased to announce that the scheme of arrangement to effect the redomiciliation of the Company and its subsidiaries from Australia to the United States of America has been implemented.

Carbios a company pioneering new bio-industrial solutions to reinvent the lifecycle of plastic and textile polymers, announced the launch of the construction of its industrial demonstration plant for the enzymatic recycling of PET plastic.